Background
Rationale
Methods
Protocol and registration
Eligibility criteria
Information sources
Search strategy and study selection
Data collection
The geometry of the network
Risk of bias
Summary measures
Analysis methods
Assessment of consistency, model fit, and convergence
Additional analyses
Results
Study selection
Study characteristics
Network structure
NO | Drug | Abbreviation | Patients |
---|---|---|---|
1 | I.V Hydration | I.V | 5136 |
2 | Statins | Sta | 3040 |
3 | Furosemide | Fur | 554 |
4 | NAC | NAC | 6095 |
5 | Trimetazidine | Tri | 352 |
6 | NaHCO3 | NaH | 3393 |
7 | PGE1 | PGE | 304 |
8 | MgSO4 | MgS | 62 |
9 | Pentoxifylline | Pen | 438 |
10 | Placebo | Pla | 7044 |
11 | Control | Con | 9120 |
12 | Allopurinol | All | 204 |
13 | BNP | BNP | 744 |
14 | Probucol | Pro | 198 |
15 | α-tocopherol | α-t | 312 |
16 | γ-tocopherol | γ-t | 102 |
17 | Oxygen | Oxy | 346 |
18 | Amlodipine and Valsartan | Aml | 45 |
19 | K/Na citrate | K/N | 203 |
20 | Nicorandil | Nic | 291 |
21 | Ascorbic Acid | Asc | 552 |
22 | Alpha-Lipoic Acid | Alp | 139 |
23 | Oral Hydration | Ora | 254 |
24 | Nebivolol | Neb | 40 |
25 | Anisodamine | Ani | 192 |
26 | RIPC | RIP | 608 |
27 | Theophylline | The | 384 |
28 | Hypothermia | Hyp | 58 |
29 | Glutathione | Glu | 421 |
30 | MESNA | MES | 51 |
31 | ACEI | AC | 129 |
32 | Aminophylline | Ami | 45 |
33 | Iloprost | Ilo | 118 |
34 | Acetazolamide | Ace | 94 |
35 | ANP | ANP | 202 |
36 | Zinc | Zin | 18 |
37 | Dialysis | Dia | 293 |
38 | Fenoldopam | Fe | 333 |
39 | ERAs | ER | 77 |
40 | CCB | CC | 42 |
41 | Dopamine | Do | 48 |
42 | Mannitol | Ma | 35 |
43 | Cordyceps | Co | 88 |
44 | Silymarin | Si | 69 |
Network geometry
Characteristic | Number |
---|---|
Number of Interventions | 44 |
Number of Studies | 200 |
Total Number of Patients in Network | 42,273 |
Total Number of Events in Network | 4602 |
Total Possible Pairwise Comparisons | 946 |
Total Number Pairwise Comparisons with Direct Data | 81 |
Number of Two-arm Studies | 179 |
Number of Multi-Arms Studies | 21 |
Number of Studies with No Zero Events | 184 |
Number of Studies With At Least One Zero Event | 16 |
Number of Studies with All Zero Events | 2 |
Risk of bias
Synthesis of results
Treatment | SUCRA | Treatment | SUCRA |
---|---|---|---|
Allopurinol | 0.9647 | NaHCO3 | 0.3419 |
MESNA | 0.9427 | Pentoxifylline | 0.3391 |
PGE1 | 0.7809 | I.V Hydration | 0.3124 |
α-tocopherol | 0.7614 | Placebo | 0.2694 |
Oxygen | 0.7527 | Oral Hydration | 0.2517 |
K/Na citrate | 0.7469 | Hypothermia | 0.2021 |
Trimetazidine | 0.7151 | Control | 0.1658 |
Probucol | 0.7042 | Amlodipine and Valsartan | 0.05485 |
γ-tocopherol | 0.689 | ACEI | 0.5783 |
BNP | 0.6767 | Aminophylline | 0.6593 |
Anisodamine | 0.6594 | Iloprost | 0.7481 |
Nicorandil | 0.6442 | Acetazolamide | 0.6242 |
Theophylline | 0.629 | ANP | 0.3291 |
RIPC | 0.5692 | Zinc | 0.198 |
Statins | 0.5497 | Dialysis | 0.4319 |
MgSO4 | 0.5177 | Fenoldopam | 0.2296 |
NAC | 0.4592 | ERAs | 0.06734 |
Nebivolol | 0.4543 | CCB | 0.7249 |
Ascorbic Acid | 0.4433 | Dopamine | 0.1916 |
Alpha-Lipoic Acid | 0.4322 | Mannitol | 0.1905 |
Furosemide | 0.4027 | Cordyceps | 0.4459 |
Glutathione | 0.3554 | Silymarin | 0.7934 |
Analysis
| Random Effects (Vague) |